Streetbeat News

Products Services

BLDR

SERV

VKTX

VRTX

Jim Cramer discussed several stocks on CNBC's 'Mad Money Lightning Round.' He praised Vertex Pharmaceuticals for its strong performance and revenue guidance increase. Builders FirstSource is recommended as a buy, while Viking Therapeutics faces challenges due to high factory costs. Serve Robotics is not recommended due to its financial losses.

Portfolio Pulse from Avi Kapoor

August 29, 2024 | 12:42 pm

BHAT

Blue Hat Interactive Entertainment Technology (NASDAQ:BHAT) has executed a $66.49 million acquisition of 1,000 kilograms of gold, marking the launch of its gold supply chain business. This strategic move aims to establish a presence in the gold market by supplying gold to refineries, wholesalers, and retailers.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:38 pm

SHOT

Safety Shot has reported clinical study results indicating that their product can rapidly reduce blood alcohol content and acetaldehyde levels, mitigating the negative effects of heavy drinking within 30 minutes.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:36 pm

CLSK

IREN

MARA

RIOT

Iris Energy aims to reach 50 EH/s in Bitcoin mining by 2025, aligning with U.S. giants like CleanSpark, Marathon, and Riot. Despite exiting power trading and losing a partner, Iris is financially strong with $405M cash and no debt, but faces rising expenses.

Portfolio Pulse from Surbhi Jain

August 29, 2024 | 12:35 pm

IVDA

Iveda has filed a patent for its LevelNOW liquid storage management IoT sensor, which is designed to enhance the monitoring and management of liquid storage systems.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:33 pm

FEMY

Femasys has received CE Mark and Health Canada approval for its FemVue MINI, a fallopian tube assessment solution. This development could enhance the company's market presence in Europe and Canada.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:32 pm

ORGS

Orgenesis Inc. announced positive results from a real-world study of its ORG-101 CAR-T therapy, showing high complete response rates in both adult and pediatric patients with CD19+ Acute Lymphoblastic Leukemia. The study also indicated a favorable safety profile with low incidence of severe Cytokine Release Syndrome. Harley Street Healthcare Group plans to collaborate with Orgenesis to establish a Global Cancer Initiative to further develop and democratize advanced therapies.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:32 pm

AFRM

BCDA

LUCY

BioCardia, Innovative Eyewear, and Affirm see significant stock price increases. BioCardia's rise follows FDA clearance for a new product, Innovative Eyewear benefits from a new sales channel, and Affirm reports strong earnings and guidance.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:24 pm

VIK

Viking has announced six new itineraries in Asia, expanding access to Japan and China, including Tibet in 2025. These voyages, ranging from 15 to 22 days, will offer exclusive access to destinations in China and Japan, with bookings now open.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:17 pm

LUCY

Innovative Eyewear's stock is rising as their Lucyd Lyte frames are now available on Target.com, potentially increasing sales and market reach.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:14 pm